Remission in autoimmune hepatitis: What is it, and can it ever be achieved?

American Journal of Gastroenterology

Volumn 102, Issue 5, 2007, Pages 1013-1015

  Al Chalabi, Thawab ^a   Heneghan, Michael A ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; PREDNISOLONE; STEROID;

ALOPECIA; AUTOIMMUNE HEPATITIS; BIOCHEMISTRY; BONE MARROW SUPPRESSION; CATARACTOGENESIS; CHOLESTATIC HEPATITIS; DIABETES MELLITUS; HISTOLOGY; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; LIVER CIRRHOSIS; NAUSEA AND VOMITING; OSTEOPOROSIS; PANCREATITIS; PREDICTION; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; REVIEW; SAFETY; SIDE EFFECT; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT; VEIN OCCLUSION;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; FEMALE; GAMMA-GLOBULINS; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RECURRENCE; REMISSION INDUCTION; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 34247895392     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2007.01147.x     Document Type: Review

References (21)

1. McFarlane IG. Autoimmune hepatitis: Diagnostic criteria, subclassifications, and clinical features. Clin Liver Dis 2002 6 : 317 33.
2. Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006 354 : 54 66.
3. Soloway RD, Summerskill WH, Baggenstoss AH, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: A controlled study of treatments and early prognosis. Gastroenterology 1972 63 : 820 33.
4. Kirk AP, Jain S, Pocock S, et al. Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut 1980 21 : 78 83.
5. Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004 40 : 646 52.
6. Dufour JF, DeLellis R, Kaplan MM. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med 1997 127 : 981 5.
7. Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002 36 : 479 97.
8. Heneghan MA, McFarlane IG. Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology 2002 35 : 7 13.
9. Heneghan MA, Allan ML, Bornstein JD, et al. Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis. J Hepatol 2006 45 : 584 91.
10. Hegarty JE, Nouri Aria KT, Portmann B, et al. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology 1983 3 : 685 9.
11. Stellon AJ, Keating JJ, Johnson PJ, et al. Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal. Hepatology 1988 8 : 781 4.
12. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995 333 : 958 63.
13. Czaja AJ, Carpenter HA. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver Int 2003 23 : 116 23.
14. Kanzler S, Gerken G, Lohr H, et al. Duration of immunosuppressive therapy in autoimmune hepatitis. J Hepatol 2001 34 : 354 5.
15. Montano-Loza AJ, Carpenter HA, Czaja AJ. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol 2007 102 : 1005 12.
16. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999 31 : 929 38.
17. Miyake Y, Iwasaki Y, Terada R, et al. Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis. J Hepatol 2005 43 : 951 7.
18. Verma S. In type 1 autoimmune hepatitis (AIH), should remission be redefined as normalization of transaminases? J Hepatol 2006 44 : 819 20.
19. Stellon AJ, Hegarty JE, Portmann B, et al. Randomised controlled trial of azathioprine withdrawal in autoimmune chronic active hepatitis. Lancet 1985 1 : 668 70.
20. Moroni G, Gallelli B, Quaglini S, et al. Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up. Nephrol Dial Transplant 2006 21 : 1541 8.
21. Holtmann MH, Krummenauer F, Claas C, et al. Long-term effectiveness of azathioprine in IBD beyond 4 years: A European multicenter study in 1176 patients. Dig Dis Sci 2006 51 : 1516 24.